SCHEDULE: Wellington Management Discloses 3.6% Stake in Revolution Medicines

Wellington Management Group LLP and its affiliates reported a 3.6% beneficial ownership stake in Revolution Medicines, Inc. common stock as of December 31, 2025.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively beneficially own 6,987,639 shares of Revolution Medicines, Inc. common stock.
• This represents 3.6% of the class of securities.
• The reporting persons hold shared voting power over 6,128,704 shares and shared dispositive power over 6,987,639 shares.
• The securities are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of Revolution Medicines, Inc.
• This filing is Amendment No. 7, indicating an update to previous ownership disclosures.
• The ownership is on behalf of clients of various Wellington Investment Advisers, with no single client known to have more than five percent of this class of securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive update. The continued presence of a major institutional investor like Wellington Management is generally positive, though the ownership percentage being below 5% and an amendment suggests a rebalancing or reduction from a prior higher stake, which is not inherently negative but warrants observation.

Positives

• Continued investment by a major institutional asset manager like Wellington Management Group LLP suggests ongoing confidence in Revolution Medicines, Inc.
• The holding is managed on behalf of clients, indicating a diversified investment strategy rather than a speculative position.

Negatives

• The beneficial ownership percentage of 3.6% is below the 5% threshold typically associated with significant activist or influential stakes, and the filing explicitly states "Ownership of 5 Percent or Less of a Class." This indicates a reduction from a previous filing where they likely held over 5%, or they are maintaining a position below 5% after an initial filing.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating the risk of activist investor intervention for Revolution Medicines, Inc.

Future Outlook

Not applicable, as this Schedule 13G filing primarily reports beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership by major asset managers like Wellington Management Group LLP is a common feature in the biotechnology and pharmaceutical sectors, where long-term investment in innovative companies is prevalent. While the 3.6% stake is below the 5% threshold for initial Schedule 13G filings, Wellington's continued disclosure indicates its ongoing presence as a significant, albeit passive, investor in Revolution Medicines, Inc. This type of institutional backing can provide stability and liquidity to a company's stock.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially influencing investor sentiment. The passive nature of the investment (not seeking control) is generally reassuring.

Key Dates

Recommendation

The filing indicates a continued, albeit passive, institutional investment by Wellington Management in Revolution Medicines. While the 3.6% stake is below the 5% threshold, it doesn't suggest a strong buy or sell signal based solely on this ownership disclosure. Investors should hold and monitor further developments from Revolution Medicines' operational and financial performance, as this filing primarily provides transparency on a significant shareholder's position rather than new fundamental information about the company's prospects.

Keywords

Revolution Medicines, Wellington Management, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals